LIFE - aTyr Pharma, Inc.
| Previous Close | 0.63 |
| Open | 0.62 |
| Bid | 0.60 x 1400 |
| Ask | 0.65 x 1400 |
| Day's Range | 0.60 - 0.66 |
| 52 Week Range | 0.60 - 6.50 |
| Volume | 575,548 |
| Avg. Volume | 1,035,714 |
| Market Cap | 18.196M |
| Beta | 3.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.66 |
| Earnings Date | Aug 13, 2018 - Aug 17, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.67 |
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of LIFE earnings conference call or presentation 14-Aug-18 9:00pm GMT
Q2 2018 aTyr Pharma Inc Earnings Call
- Associated Press•2 days ago
Atyr Pharma: 2Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 35 cents. In the final minutes of trading on Tuesday, the company's shares hit 66 cents. A year ago, they were trading at $3.25. ...
- GlobeNewswire•2 days ago
aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
SAN DIEGO, Aug. 14, 2018-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating ...
- ACCESSWIRE•2 days ago
aTyr Pharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 5:00 PM Eastern Time. ...
- GlobeNewswire•8 days ago
aTyr Pharma to Host Conference Call and Webcast of Second Quarter 2018 Financial Results on August 14, 2018
SAN DIEGO, Aug. 08, 2018-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will ...
- GlobeNewswire•17 days ago
aTyr Pharma Appoints Jill Broadfoot as Chief Financial Officer
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Jill Broadfoot has joined aTyr as Chief Financial Officer. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals plc, from May 2016 to January 2017.
- GlobeNewswire•22 days ago
aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster presentation at the Scleroderma Foundation National Patient Education Conference to be held in Philadelphia, PA from July 27 – 29, 2018. The presentation reviews the positive lung and skin results of a recently completed murine experiment evaluating low doses of ATYR1923 in a chronic graft versus host disease model of systemic sclerosis. “The data we are presenting tomorrow are part of our ongoing estate of translational animal models set to help inform and de-risk our upcoming clinical development of ATYR1923,” stated David King, Ph.D., aTyr’s Chief Scientific Officer.
- GlobeNewswire•2 months ago
aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate
SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced positive data from its Phase 1 clinical trial of ATYR1923, an immuno-modulatory therapeutic candidate with potentially broad therapeutic application in the treatment of interstitial lung diseases. This first-in-human, randomized, double-blind, placebo-controlled study was designed to investigate the safety, tolerability, immunogenicity and pharmacokinetics of intravenous ATYR1923 in healthy volunteers. The Phase 1 study enrolled 36 healthy volunteers who were randomized to one of six cohorts and received a single infusion of intravenous ATYR1923 or placebo.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of LIFE earnings conference call or presentation 19-Mar-18 9:00pm GMT
Q4 2017 aTyr Pharma Inc Earnings Call
- GlobeNewswire•3 months ago
aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference
SAN DIEGO, May 31, 2018-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of LIFE earnings conference call or presentation 14-May-18 12:00pm GMT
Q1 2018 aTyr Pharma Inc Earnings Call
- Associated Press•3 months ago
Atyr Pharma: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 36 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- ACCESSWIRE•3 months ago
aTyr Pharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 14, 2018 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 8:00 AM Eastern Time. To listen ...
- Zacks•5 months ago
aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?
aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?
- Associated Press•5 months ago
Atyr Pharma reports 4Q loss
The San Diego-based company said it had a loss of 39 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
- ACCESSWIRE•5 months ago
aTyr Pharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 19, 2018 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018, at 5:00 PM Eastern Time. ...
